PMID- 36224294
OWN - NLM
STAT- MEDLINE
DCOM- 20221014
LR  - 20221229
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Oct 12
TI  - Effect of empagliflozin versus linagliptin on body composition in Asian patients 
      with type 2 diabetes treated with premixed insulin.
PG  - 17065
LID - 10.1038/s41598-022-21486-9 [doi]
LID - 17065
AB  - Insulin therapy often increases body weight and leads to visceral fat 
      accumulation. Progression in diabetes is also associated with accelerated loss of 
      muscle mass. Little is known about body composition changes in type 2 diabetes 
      mellitus (T2DM) patients on insulin therapy who use sodium-glucose 
      cotransporter-2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) 
      inhibitors. This study examined the effect of 25 mg of empagliflozin compared 
      with 5 mg of linagliptin for 24 weeks on body weight and body composition in 
      patients with T2DM on premixed insulin. Body composition was assessed with 
      bioelectrical impedance analysis. The mean difference between the linagliptin and 
      empagliflozin groups in terms of mean body weight change from baseline to 
      24 weeks was - 1.80 kg (95% CI - 2.57, - 1.03). Empagliflozin also significantly 
      reduced muscle mass (- 1.39 kg, 95% CI - 2.49, - 0.29) and total body water 
      (- 1.07 kg, 95% CI - 1.88, - 0.27) compared with linagliptin. Compared to 
      linagliptin, empagliflozin decreased body fat mass more from baseline to week 24, 
      but this was not significant (- 0.31 kg, 95% CI - 1.51, 0.90). Further research 
      on insulin-treated T2DM patients is necessary to investigate the long-term 
      effects of SGLT2 and DPP4 inhibitors on body composition, as well as their 
      effects on muscle strength and physical function.Trial registration: 
      ClinicalTrials.gov no. NCT03458715, registration date: March 8, 2018.
CI  - (c) 2022. The Author(s).
FAU - Zeng, Yi-Hong
AU  - Zeng YH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay 
      Memorial Hospital, Taipei, Taiwan.
AD  - Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
AD  - Institute of Public Health, National Yang Ming Chiao Tung University, No. 155, 
      Sec. 2, Linong St., Beitou District, Taipei City, 112, Taiwan.
FAU - Liu, Sung-Chen
AU  - Liu SC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay 
      Memorial Hospital, Taipei, Taiwan.
AD  - Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
FAU - Lee, Chun-Chuan
AU  - Lee CC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay 
      Memorial Hospital, Taipei, Taiwan.
AD  - Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
FAU - Sun, Fang-Ju
AU  - Sun FJ
AD  - Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan.
AD  - MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan.
AD  - Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, 
      Taipei, Taiwan.
FAU - Liu, Jason J
AU  - Liu JJ
AD  - Institute of Public Health, National Yang Ming Chiao Tung University, No. 155, 
      Sec. 2, Linong St., Beitou District, Taipei City, 112, Taiwan. 
      jasonjliu.jjl@gmail.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT03458715
PT  - Clinical Study
PT  - Journal Article
DEP - 20221012
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 9NEZ333N27 (Sodium)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
RN  - HDC1R2M35U (empagliflozin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Benzhydryl Compounds
MH  - Blood Glucose
MH  - Body Composition
MH  - Body Weight
MH  - *Diabetes Mellitus, Type 2
MH  - Dipeptidyl Peptidase 4
MH  - *Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use
MH  - Glucose
MH  - Glucosides
MH  - Humans
MH  - Hypoglycemic Agents
MH  - Insulin
MH  - Linagliptin/therapeutic use
MH  - Sodium
MH  - Sodium-Glucose Transporter 2/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Treatment Outcome
PMC - PMC9556548
COIS- The authors declare no competing interests.
EDAT- 2022/10/13 06:00
MHDA- 2022/10/15 06:00
PMCR- 2022/10/12
CRDT- 2022/10/12 23:26
PHST- 2021/11/21 00:00 [received]
PHST- 2022/09/27 00:00 [accepted]
PHST- 2022/10/12 23:26 [entrez]
PHST- 2022/10/13 06:00 [pubmed]
PHST- 2022/10/15 06:00 [medline]
PHST- 2022/10/12 00:00 [pmc-release]
AID - 10.1038/s41598-022-21486-9 [pii]
AID - 21486 [pii]
AID - 10.1038/s41598-022-21486-9 [doi]
PST - epublish
SO  - Sci Rep. 2022 Oct 12;12(1):17065. doi: 10.1038/s41598-022-21486-9.